What were the main drivers of Boston Scientific's revenue growth in 2016?

Revenue growth in 2016 was primarily driven by strong performance in the company's key segments, including Cardiovascular, Rhythm Management, and Endoscopy. Expansion in international markets, particularly in emerging economies, also contributed significantly to the top-line results.

How is Boston Scientific investing in future growth?

Boston Scientific is strategically investing in Research and Development (R&D) to advance its product pipelines and bring innovative medical solutions to market. This includes developing next-generation devices and exploring new therapeutic areas to maintain a competitive edge.

What is the company's strategy regarding acquisitions and divestitures?

The company engages in strategic acquisitions and divestitures to optimize its product portfolio, gain access to new technologies, and strengthen its market position in high-growth areas. These moves are designed to enhance long-term profitability and shareholder value.

What is the company's outlook for profitability?

Boston Scientific is focused on improving profitability through operational efficiencies, cost management initiatives, and the successful commercialization of its innovative products. The company expresses confidence in its ability to achieve sustained growth and enhance shareholder returns.

BSX 10-K FY2016 Annual Report — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) filed its 2016 annual report on Form 10-K, presenting a comprehensive overview of its financial performance and strategic positioning. The report highlights the company's continued focus on innovation and growth across its diverse medical device segments. Investors should note the company's revenue drivers and its ongoing efforts to manage costs and optimize its product portfolio. Key areas of attention include the performance of its cardiovascular, rhythm management, and endoscopy divisions, as well as its strategic acquisitions and divestitures aimed at enhancing market share and profitability. The company's financial results for 2016 demonstrate a commitment to operational efficiency and strategic execution. BSX has been actively investing in research and development to bring new products to market and expand its global reach. While navigating a competitive healthcare landscape, Boston Scientific appears to be making strides in key therapeutic areas, positioning itself for sustained growth. Investors will want to closely examine the company's balance sheet, cash flow generation, and its outlook for the coming fiscal year.

Financial Highlights

53 data points

Beta

Revenue

$8.39B

0.7% Gross Margin

Net Income

$347.00M

0.0% Net Margin

EPS (Diluted)

$0.25

Total Assets

$18.10B

Cash & Equivalents

$196.00M

Free Cash Flow

$806.00M

Financial Statements

Beta

Revenue	$8.39B
Cost of Revenue	$2.42B
Gross Profit	$5.96B
SG&A Expenses	$3.10B
Operating Expenses	$5.51B
Operating Income	$447.00M
Interest Expense	$233.00M
Net Income	$347.00M
EPS (Basic)	$0.26
EPS (Diluted)	$0.25
Shares Outstanding (Basic)	1.36B
Shares Outstanding (Diluted)	1.38B

Key Highlights

1Revenue growth driven by strong performance in key product categories and geographical regions.
2Continued investment in Research and Development (R&D) to fuel innovation and new product pipelines.
3Strategic acquisitions and divestitures aimed at portfolio optimization and market expansion.
4Focus on operational efficiency and cost management to improve profitability.
5Expansion of global presence and market penetration in emerging economies.
6Management's confidence in future growth prospects and strategic direction.

BOSTON SCIENTIFIC CORP Annual Report (Amendment), Year Ended Dec 31, 2016

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions